These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34001345)

  • 1. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis.
    Awad AM; Ntoso A; Connaire JJ; Hernandez GT; Dhillon K; Rich L; Henderson H; Lynn R; Hyer RN; Xie F; Erby K; Janssen RS;
    Vaccine; 2021 Jun; 39(25):3346-3352. PubMed ID: 34001345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
    Girndt M; Houser P; Manllo-Karim R; Ervin JE; Charytan C; Chow S; Symonian-Silver M; Lehrner L; Linfert D; Shemin D; Michelsen A; Xie F; Janssen RS
    Vaccine; 2023 May; 41(20):3224-3232. PubMed ID: 37085451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.
    Girndt M; Plüer M; Dellanna F; Michelsen AK; Beige J; Toussaint K; Wehweck HJ; Koch M; Hafezi Rachti S; Faust J; Bosselmann HP; Witzke O; Janssen RS;
    Hum Vaccin Immunother; 2022 Nov; 18(6):2136912. PubMed ID: 36269938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis.
    Manley HJ; Aweh G; Frament J; Ladik V; Lacson EK
    Nephrol Dial Transplant; 2023 Feb; 38(2):447-454. PubMed ID: 35150277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibody persistence following booster vaccination with three doses of hepatitis B vaccines among low-response adults in Zhangqiu county of Shandong province: 24-month of follow-up from 2009].
    Yan B; Lyu J; Liu J; Feng Y; Xu A; Chen S; Zhou L; Liang X; Cui F; Wang F; Zhang L
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Dec; 48(12):1043-7. PubMed ID: 25619213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
    Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
    Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update.
    Lee GH; Lim SG
    Expert Rev Vaccines; 2021 May; 20(5):487-495. PubMed ID: 33783302
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination.
    Zhao YL; Han BH; Zhang XJ; Pan LL; Zhou HS; Gao Z; Hao ZY; Wu ZW; Ma TL; Wang F; Li Q; Bi SL; Ma JC
    BMC Infect Dis; 2019 May; 19(1):482. PubMed ID: 31146699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.
    Marks KM; Kang M; Umbleja T; Avihingsanon A; Sugandhavesa P; Cox AL; Vigil K; Perazzo H; Price JC; Katsidzira L; Vernon C; Alston-Smith B; Sherman KE;
    Clin Infect Dis; 2023 Aug; 77(3):414-418. PubMed ID: 37017075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant.
    Champion CR
    Ann Pharmacother; 2021 Jun; 55(6):783-791. PubMed ID: 32988213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
    Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D
    Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.
    Vesikari T; Finn A; van Damme P; Leroux-Roels I; Leroux-Roels G; Segall N; Toma A; Vallieres G; Aronson R; Reich D; Arora S; Ruane PJ; Cone CL; Manns M; Cosgrove C; Faust SN; Ramasamy MN; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson D; Popovic V; Diaz-Mitoma F;
    JAMA Netw Open; 2021 Oct; 4(10):e2128652. PubMed ID: 34636914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of booster dose vaccination 21- to 32-years after primary vaccination with hepatitis B vaccine in the population born from 1986 to 1996 in Zhengding County of Hebei Province].
    Zhang XJ; Wu ZW; Zhang YH; Li MJ; Zhou HS; Han BH; Hao ZY; Chu J; Gao Z; Ma JC; Zhao YL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):942-946. PubMed ID: 32907282
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among non-responsive adults: a 4-year of follow-up study].
    Zhang L; Yan BY; Lyu JJ; Liu JY; Feng Y; Wu WL; Cao CZ; Chen SY; Zhou LB; Liang XF; Cui FQ; Wang FZ; Zhang GM; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Jun; 50(6):497-502. PubMed ID: 27256728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
    Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
    Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: A retrospective chart review.
    Kushner T; Huang V; Janssen R
    Vaccine; 2022 May; 40(21):2899-2903. PubMed ID: 35430105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
    Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
    Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-HBs persistence after revaccination with three doses of hepatitis B vaccines among non-responsive adults: 24-month of follow-up].
    Zhang L; Lyu J; Yan B; Liu J; Feng Y; Chen S; Zhou L; Liang X; Cui F; Wang F; Xu A
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Sep; 49(9):782-7. PubMed ID: 26733135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.